Immune checkpoint inhibitors in combination with radiotherapy as salvage treatment for relapsed/refractory classical Hodgkin lymphoma: A retrospective analysis in 12 patients
| العنوان: | Immune checkpoint inhibitors in combination with radiotherapy as salvage treatment for relapsed/refractory classical Hodgkin lymphoma: A retrospective analysis in 12 patients |
|---|---|
| المؤلفون: | Manuela Caizzi, Elisa Lucchini, Francesco Zaja, Anna Schiattarella, Stefano Volpetti, Armando Santoro, Mario Levis, Chiara Rusconi, Francesca Ricci, Fabio Matrone, Umberto Ricardi, Anna Di Russo |
| المساهمون: | Lucchini, E., Rusconi, C., Levis, M., Ricci, F., Santoro, A., Ricardi, U., Volpetti, S., Matrone, F., Di Russo, A., Caizzi, M., Schiattarella, A., Zaja, F. |
| المصدر: | Hematology Reports, Vol 13, Iss 2 (2021) Hematology Reports Hematology Reports; Volume 13; Issue 2; Pages: 9080 |
| بيانات النشر: | PAGEPress Publications, 2021. |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | Oncology, medicine.medical_specialty, medicine.medical_treatment, Immune checkpoint inhibitors, Pembrolizumab, Article, Autologous stem-cell transplantation, ICI-RT, Refractory, Internal medicine, Classical Hodgkin lymphoma, medicine, polycyclic compounds, Diseases of the blood and blood-forming organs, Brentuximab vedotin, radiotherapy, Radiotherapy, Nivolumab, pembrolizumab, Hodgkin lymphoma, business.industry, Hematology, Radiation therapy, RC633-647.5, business, hormones, hormone substitutes, and hormone antagonists, medicine.drug |
| الوصف: | The rate of complete remission (CR) with the anti-PD1 immune checkpoint inhibitors (ICI) nivolumab (N) and pembrolizumab (P) in patients with relapsed/refractory (R/R) classical Hodgkin lymphoma (cHL) is low (20–30%), and the majority of patients eventually relapse. One strategy to improve their outcome is to combine ICI with radiotherapy (ICI-RT), taking advantage of a supposed synergistic effect. We retrospectively collected data of 12 adult patients with R/R cHL treated with ICI-RT delivered during or within 8 weeks from the start or after the end of ICI. Median age at ICI-RT was 37 years, 50% had previously received an autologous stem cell transplantation (SCT) and 92% brentuximab vedotin. RT was given concurrently, before or after ICI in 4, 1 and 7 patients. Median RT dose was 30 Gy, for a median duration of 22 days. Median number of ICI administrations was 15. Overall response and CR rate were 100% and 58%. Nine patients received subsequent SCT consolidation (7 allogeneic and 2 autologous). After a median follow-up of 18 months, 92% of patients were in CR. No major concerns about safety were reported. ICI-RT combination appears to be a feasible and highly active bridge treatment to transplant consolidation. |
| وصف الملف: | application/pdf |
| اللغة: | English |
| تدمد: | 2038-8330 2038-8322 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f9c3f8eaf05ebdaf599685cfd6041faaTest https://www.pagepress.org/journals/index.php/hr/article/view/9080Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....f9c3f8eaf05ebdaf599685cfd6041faa |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 20388330 20388322 |
|---|